

## INFORMATION STATEMENT

*Stockholm, February 20, 2006*

### **TFS Phase I / IIa Unit exceeds all expectations in Q1 2006**

The phase I / IIa Unit located at the distinguished Karolinska University Hospital exceeds all operational expectations set for the year 2006. The unit has during the first quarter in 2006 been awarded 13 phase I studies – all to be conducted during 2006. TFS has also in the first quarter received requests for proposals for additional six phase I studies to commence in mid and late 2006. The phase I / IIa Unit was established at the Karolinska University Hospital by TFS in early 2003.

"We can clearly see that our investment in facilities and state-of-the-art equipment is paying off and that our strategy in establishing such a Unit was the right decision. We did expect a peak of phase I studies during 2006 and 2007, but the current situation has exceeded all our expectations", says the Chief Executive Officer at TFS, Mr. Daniel Spasic. "We are now seeking possibilities to increase our engagement at the hospital in order to open up more space and beds to future studies" says Mr. Spasic.

The sponsors represent a diversified segment of large pharmaceutical-, smaller biotechnological- and a number of medical device companies. The variation of studies includes different areas such as Positron Emission Tomography (PET), microdosing, traditional bio-equivalence and surgical interventions of implants and catheters.

"These are challenging times for us, since we must adopt to each specific study and also train our personnel to be prepared to work in this very changing day-to-day environment with all these very different studies" says Director of early drug development, Mr. Niklas Lindberg. "We are also seeing how the phase I studies are starting to include patients to a greater extent and becoming larger in size, reflecting the trend to seek early PoC models already in phase I" continues Mr. Lindberg.

Early detection of PoC is also creating an interest in small phase 0 studies including 3 to 5 healthy volunteers and the number of such studies is expected to increase the coming years, especially by including microdosing and PET to more studies.

"Karolinska University Hospital is well known all over the world for its frontline skills in highly specialized medical treatments and research achievements", says associate professor and senior consultant Pierre Lafolie. He heads the Karolinska Clinical Research where the TFS Phase I / IIa Unit is located. "We have met an ever increasing demand on our services from the very first day. The benefit for the hospital is exciting scientific collaborations on new investigational products with a possibility of delivering new medicinal landmarks to our patients. We are very happy with our contacts today including customers from Japan, India, US and Europe. I think the reason behind this remarkable development is our devoted team" continues Dr. Lafolie.



TFS TRIAL FORM SUPPORT INTERNATIONAL AB